Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Valeant to Buy Medicis Pharmaceutical in $2.6 Billion Deal

Don't Miss Out —
Follow us on:

Sept. 3 (Bloomberg) -- Valeant Pharmaceuticals International, Inc. said it agreed to buy Medicis Pharmaceutical Corp. in a transaction valued at about $2.6 billion.

Valeant, in what it described as a “definitive agreement,” said it would acquire all Medicis shares outstanding for $44 each in cash. The purchase price represents an approximate 39 percent premium to Medicis’ closing price of $31.56 on Aug. 31 in New York composite trading.

The agreement was unanimously approved by the boards of directors of both companies, the companies said in a joint statement. The transaction is expected to close sometime during the first two quarters of next year.

The acquisition is a move by Valeant “to become a leader in dermatology” by expanding the company’s “presence in acne, actinic keratosis, aesthetic injectables and anti-virals, among others,” said Chairman and Chief Executive Officer J. Michael Pearson in a statement.

The transaction is subject to several conditions, including approval by Medicis stockholders and expiration of any applicable regulatory waiting period. Valeant expects the transaction, once completed, to be immediately accretive to Valeant’s cash earnings per share.

Link to Statement:{NSN M9SCO33PWT1C <GO>}

Link to Company News:{MRX US <Equity> CN <GO>} Link to Company News:{VRX CN <Equity> CN <GO>}

To contact the editor responsible for this story: Theo Mullen at tmullen11@bloomberg.net